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Abstract
Recent successes of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV infection
have raised questions whether further placebo controlled trials of new HIV-prevention
technologies are ethically justifiable. A trial with active agent(s) in the comparator group can be
designed either as a superiority or non-inferiority trial. In a non-inferiority trial the hypothesis
tested is that the intervention is not inferior to, by a predefined clinically relevant amount, or at
least as effective as, the comparator. Non-inferiority trials pose challenges in data interpretation.
Firstly it is possible to show equivalence of two non-effective interventions. If the active
comparator intervention is ineffective, the new intervention would be shown to be non-inferior to
this inactive intervention, while neither intervention is superior to placebo or no intervention. The
second challenge is that any effect that dilutes the true efficacy of an intervention in a trial, such as
non-adherence, loss to follow-up or protocol violations, makes it easier for the two interventions
to be declared equivalent. Non-differential low adherence is unlikely to lead to the conclusion that
an inferior intervention is non-inferior. However, differential adherence between study arms,
which is more likely in non-blinded trials, is likely to bias the results and lead to incorrect
conclusions.
Investigators conducting non-inferiority trials will have to pay special attention to supporting,
measuring and maintaining high adherence. The goal in future non-inferiority trials should be to
maintain similar levels of high adherence in all study arms, but at a minimum to reduce the
likelihood of differential adherence across study arms.
INTRODUCTION
Several randomized placebo-controlled trials of microbicides or antiretroviral pre-exposure
prophylaxis (PrEP) have been conducted to assess their effectiveness in preventing sexual
transmission of HIV infection. Prior to 2010, none of these trials had demonstrated
effectiveness in preventing HIV [1]. In July 2010, a microbicide gel containing the
antiretroviral drug tenofovir (CAPRISA 004) demonstrated 39% reduction in HIV-
acquisition in women [2] and in November 2010, oral emtricitabine and tenofovir disoproxil
fumarate (FTC–TDF) showed 44% reduction in HIV-acquisition (iPrEx) in men who have
sex with men [3]. While oral FTC-TDF (FEM-PrEP) [4] and oral TDF (VOICE) [5] were
not found to be effective in heterosexual women, two trials showed in July 2011 that oral
TDF and FTC-TDF were found to reduce HIV-transmission by 62% and 73% in
serodiscordant couples (Partners PrEP) [6] and oral FTC-TDF reduced HIV-transmission by
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63% in heterosexual men and women (TDF2) [7]. Furthermore, early antiretroviral
treatment initiation in the HIV-positive partner (HPTN052) was shown to reduce HIV
acquisition from the positive partner in the HIV-negative partner in serodiscordant couples
by 96% [8]. These recent successes have raised questions about the design of future HIV
prevention trials and whether further placebo controlled trials of some new HIV-prevention
technologies are ethically justifiable [9].
As long as evidence about the efficacy of PrEP in preventing HIV infection is ambiguous,
future placebo controlled trials are required. Currently estimates of the efficacy of daily oral
FTC-TDF in women ranges from no efficacy [4] to 73% [6]. However, there is hope that
accumulating evidence may demonstrate a more consistent estimate of PrEP effectiveness in
the near future. In this scenario, future placebo controlled trials may no longer be possible.
One option for future trials which are designed to assess the efficacy of new HIV prevention
strategies is to include these efficacious antiretroviral intervention(s) in both intervention
and control arms. In this case, the net effect is to lower the overall HIV incidence rate in the
trial thereby making the trial larger and/or longer. This could add substantially to the cost of
the trial. In some instances, it may not be safe, feasible or practical to implement a known
efficacious antiretroviral intervention simultaneously in a trial as it may interfere with the
new study intervention under investigation. For example, the use of a vaginal ring
containing an antiretroviral may be a contra-indication for the simultaneous use with a gel
containing the same or a different antiretroviral. In such cases, another option is to include
efficacious antiretroviral intervention(s) only in the comparator group.
A trial with active agent(s) in the comparator group can be designed either as a superiority
or non-inferiority trial. In a superiority trial, the hypothesis tested is that the new
intervention under investigation is better, by a clinically relevant amount, than the
comparator, which can be either standard of care, placebo or another active intervention.
This can be done either as a blinded or open label trial. The new intervention needs to be
even more potent than an active comparator in order to show superiority i.e. higher efficacy.
In a non-inferiority trial the hypothesis being tested is that the intervention under
investigation is not inferior to, by a predefined clinically relevant amount, or at least as
effective as, the comparator [10]. Non-inferiority trials are used when the new intervention
is assumed to have some benefits (e.g. improved safety, low cost, etc) over the comparator
intervention, but has similar efficacy [11]. Non-inferiority trials, however, are not without
challenges in data interpretation [12].
The first challenge is that any intervention can easily be shown to be non-inferior to a non-
effective comparator intervention; whether or not either intervention is superior to placebo
or no intervention [10].
The assumption made when an active comparator is used in a non-inferiority trial is that the
efficacy found in another trial also applies to the population and environment in the current
trial; an assumption that cannot, in most instances be readily tested. How similar do two
populations need to be before findings in one population can be used to determine the active
comparator in another population? For example, can we assume that oral FTC–TDF will be
44% effective in a population of heterosexual women, because it was found to be 44%
effective in a population of men who have sex with men? [3] The validity of this assumption
was challenged by the findings of a trial testing FTC-TDF in a population of heterosexual
women (FEM-PrEP) where no protection against HIV was shown [4], while 73%
effectiveness was found in men and women in serodiscordant relationships (Partners PrEP)
[6].
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Consider a hypothetical new PrEP trial testing coital use of oral tenofovir against daily use
of oral tenofovir which concluded equivalence; i.e. concluded that coital use of oral
tenofovir is not inferior to daily oral tenofovir. If we drew this conclusion in August 2011,
before the recent findings of the VOICE study [5], we would have concluded that coital
tenofovir is 62% effective, based on the effectiveness of daily oral tenofovir in the Partners
PrEP trial [6]. If, however, we drew this conclusion 3 months later in October 2011, after the
recent announcement from the VOICE study, we could conclude that coital tenofovir is not
effective. Without a clear and consistent protective efficacy estimate for daily oral tenofovir,
it is difficult to provide a meaningful interpretation of a non-inferiority trial assessing coital
use of oral tenofovir.
The second challenge is that any effect that dilutes the true efficacy of an intervention in a
trial such as non-adherence to the study regimen, considerable loss to follow-up or protocol
violations, makes it easier for the two interventions to be declared equivalent. Non-
adherence is a particular concern in these settings because it difficult to reliably measure
adherence levels in both arms of a PrEP trial. Drug level monitoring is only a partial
solution, since this can only be done in the active arm. A placebo with a biological marker of
adherence could address this. A poorly conducted trial will be more likely to lead to the false
conclusion that the test intervention is non-inferior to the active comparator than a well
conducted trial [10].
The standard approach to dealing with this problem is to base the primary analysis of a non-
inferiority trial on the per protocol population and not on the intent-to-treat population, as is
standard with a superiority trial. This is because the intent-to-treat analysis is biased towards
equality in conditions where many participants did not follow study procedures. One of the
most important criteria for inclusion in the per protocol analysis is adherence to the study
regimen. In the CAPRISA 004 [2], iPrEx [3], Partners PrEP [6] and FEM-PrEP trials [4],
self-reported adherence and adherence based on applicator or pill count was high. In the
iPrEx trial there was a poor correlation between reported adherence and drug levels
detected. This casts doubts on both the adherence during this trial and on the validity of self-
report. If adherence is not accurately measured, an analysis based on adherence or on the per
protocol population determined by adherence may lead to incorrect conclusions. More
reliable measures of adherence such as drug concentrations in the active arm could go some
way towards increasing the likelihood of high adherers being included in the active arm of
the per protocol analysis. A biological adherence marker will be needed for the placebo arm
for a valid comparison.
The importance of adherence in non-inferiority trials should not be underestimated. Sub-
optimal adherence in a trial with an active comparator has the net effect of making the result
“flatter” but does not lead to an erroneous conclusion of non-inferiority, provided adherence
levels are similar in each of the study arms (Table 1). The exception occurs when adherence
is zero or very close to zero in each of the treatment arms; in this case non-inferiority is
invariably declared.
Differential adherence in the study arms is much more complex and, under a range of
scenarios, can lead to incorrect conclusions (Table 1). If the true effectiveness of both
interventions are the same, the intervention with higher adherence is favored in a non-
inferiority study. If an inferior, but still efficacious, intervention had higher adherence than
the more effective comparator, a conclusion of non-inferiority would be made.
Adherence to an intervention is an important determinant of whether a prevention strategy
would have a public health benefit; therefore the adherence to an intervention is an
important aspect of the determination of its efficacy. However, if adherence to the
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comparator is low; one might in effect be comparing a new intervention to a placebo-like
effect created by lack of adherence to the intervention even though this comparator was
intended to be an active intervention.
Differential adherence is unlikely in a double blinded trial of similar interventions; where
neither the study participants, nor the investigators are aware of study assignment. However,
differential adherence is much more likely where the comparator and the new intervention
are substantially different and blinding is less likely. More specifically, if one intervention is
an oral formulation and the other intervention is topical, different patterns of use might be
likely and adherence might differ substantially. The same holds for different dosing
strategies; for example where once daily dosing is compared to coitally dependent dosing.
Differential adherence is also likely when the interventions have different side effect
profiles. Although no evidence of differential adherence was found in the CAPRISA 004
trial [2], differential adherence was reported in the iPrEx trial in some of the early visits,
with lower adherence in the active arm [3], probably due to drug side effects.
Extreme caution should be used when non-inferiority studies are planned comparing
different dosing strategies, which are likely to lead to different adherence levels. It might not
be possible to compare formulations that are very different, such as oral, ring and gel
formulations, as they are likely to be used differentially.
The third challenge with non-inferiority trials is their large size, much larger than superiority
trials [12]. The PrEP trials which have recently announced results were all designed as
superiority trials with sample sizes between 1000 and 5000 participants. The topical PrEP
trial targeted 92 HIV infections[2], while the oral PrEP trial targeted 85 infections. In
contrast, a non-inferiority trial with 80% power to show an intervention not more than 20%
inferior to the active comparator would require about 500 HIV infections. A non-inferiority
limit of 20% is probably too large if the active comparator is only 40% effective, but small
enough if the active comparator is 60 to 70% effective.
Conclusions
In future efficacy trials of new HIV prevention interventions, non-inferiority designs may
become one of the standard approaches. These designs are harder to interpret and care
should be taken to ensure that comparison treatments are well understood.
In these study designs, adherence is a critical factor as it may lead to spurious results.
Differential adherence in the treatment arms could lead to incorrect findings about the true
effectiveness of the interventions. Investigators conducting non-inferiority trials will, of
necessity, have to pay special attention to supporting, measuring and maintaining high
adherence. The effect of differential adherence between study arms should be considered
when interpreting the results.
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